WHO Consultation: PPC and clinical development considerations for malaria vaccines
The WHO Global Malaria Programme (GMP) is seeking public comments on the following preferred product characteristics (PPC) and clinical development considerations for malaria vaccines.
The primary target audience for this malaria vaccine PPC is any entity involved in malaria vaccine development, especially those intending to seek a WHO policy recommendation and prequalification for their product. PPCs are intended to encourage innovation and development of vaccines that perform in settings most relevant to the global unmet public health need.
The malaria vaccine PPCs are aligned to the strategic priorities of the WHO and partners. More specifically, the Malaria Vaccine Technology Roadmap encourages efforts to address the following unmet priority public health goals:
- Strategic goal 1: Malaria vaccines against clinical malaria, suitable for administration to appropriate at-risk groups in malaria-endemic areas.
- Strategic goal 2: Malaria vaccines that reduce transmission of the parasite and thereby substantially reduce the incidence of human malaria infection.
Read the draft for consultation here.
Interested parties can provide comments using the following online survey.
Survey deadline June 30, 2021.
